| HCV | Hepatitis C Virus |
| 4-PBA | 4-Phenyl butyrate |
| HDACi | Histone Deacetylase Inhibitor |
| HCC | Hepatocellcular Carcinoma |
| DAAs | Direct Acting antiviral reagents |
| FDA | Food and Drug Administration |
| ER | Endoplasmic Reticulum |
| AMPs | Antimicrobial Peptides |
| HCV | Hepatitis C Virus |
| 4-PBA | 4-Phenyl butyrate |
| HDACi | Histone Deacetylase Inhibitor |
| HCC | Hepatocellcular Carcinoma |
| DAAs | Direct Acting antiviral reagents |
| FDA | Food and Drug Administration |
| ER | Endoplasmic Reticulum |
| AMPs | Antimicrobial Peptides |